NVP-AAL881

NVP-AAL881 is a small molecule inhibitor developed by Novartis that targets multiple kinases involved in cancer angiogenesis and growth. Specifically, it functions as a dual inhibitor of **RAF kinases** (including BRAF and CRAF) and **VEGF receptor 2 (VEGFR2/KDR)**. The drug blocks signaling pathways critical for tumor cell proliferation and angiogenesis. In preclinical models, NVP-AAL881 significantly inhibited tumor growth, decreased vascularization (CD31-vessel area), and reduced tumor cell proliferation (BrdU labeling). Its mechanism includes **BRAF inhibition, CRAF inhibition, and VEGFR2 antagonism**[1][3][5].

Other names

NVP-AAL881NVP-AAL-881NVP-AAL 881AAL-881AAL881AAL 881